drugset / Trial / NCT00276835
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Interleukin-2 may stimulate the white blood cells, including natural killer cells, to kill melanoma or kidney cancer cells. Giving genistein together with interleukin-2 may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving genistein together with interleukin-2 works in treating patients with metastatic melanoma or kidney cancer.
Timeline
- Start
- 2005-11
- Primary completion
- 2007-07
- Completion
- 2014-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Genistein | Other / unclassified | 300 mg | Oral |
| Subject | aldesleukin | Protein / enzyme biologic | 600000 iu/kg | Intravenous |